

NEWS RELEASE

Kuala Lumpur/Singapore, 29 August 2024

IHH Healthcare reports strong double-digit growth in Q2 2024

- **Q2 2024:** revenue up 30%, EBITDA up 34%, PATMI (ex EI) up 39%, PATMI up 107%
- **H1 2024:** sustained core operational growth momentum

“We delivered an outstanding first half 2024 performance, highlighted by two straight quarters of record revenue contribution and continued operational excellence across all our core markets. All our key financial metrics reported strong double-digit growth.

Providing quality patient care and excellent outcomes remains our key priority. Recently, we broke ground on IHH Singapore’s first foray into a transitional care facility, extending our continuum of care. Additionally, Fortis Memorial Research Institute in India became the first in South Asia to offer Gamma Knife Esprit treatment for brain tumours, solidifying our position as Asia’s leading centre of excellence for cancer care.

As we continue to strengthen our healthcare leadership and drive growth across our strategic priorities, we are confident of delivering sustainable value for all stakeholders.”

Dr Prem Kumar Nair
Group Chief Executive Officer, IHH Healthcare

GROUP RESULTS – FINANCIAL HIGHLIGHTS¹
Q2 2024 key metrics (Y-o-Y) change

Revenue	EBITDA	PATMI (ex EI)	PATMI
RM6.1b	RM1.4b	RM437m	RM623m
+30%	+34%	+39%	+107%

H1 2024 key metrics (Y-o-Y) change

Revenue	EBITDA	PATMI (ex EI)	PATMI
RM12.0b	RM2.7b	RM840m	RM1.4b
+23%	+26%	+30%	-18%

¹ The Group’s headline performance includes the application of the MFRS 129 accounting standard (Financial Reporting in Hyperinflationary Economies) relating to its entities in Türkiye.

GROUP OPERATIONAL SUMMARY (FOR QUARTER ENDED 30 JUNE 2024)



Occupancy

(for Q2 2024)

70%



Inpatient Admissions

(for Q2 2024)

222,204



Operational Beds

(as at 30 June 2024)

12,220



Lab Tests

(for Q2 2024)

25 million

Q2 2024: Outstanding core performance with strong double-digit growth across all key metrics


- Revenue and EBITDA grew to RM6.1 billion and RM1.4 billion respectively, on sustained patient volume growth and taking on more acute, complex cases across all markets.
- PATMI more than doubled on the strong operational performance, as well as positive impact from deferred tax credits and net monetary gains from the application of MFRS 129.
- Excluding exceptional items, PATMI (ex EI) grew by 39%.
- To further elevate IHH as a global healthcare leader, the Group has in recent months:
 - Made key appointments to the Board of Directors, including:
 - Tan Sri Dr Nik Norzrul Thani Nik Hassan Thani as Chairman and Independent Non-Executive Director on 26 June 2024.
 - Ms Chua Bin Hwee as Audit Committee Chairman and Independent Non-Executive Director on 14 August 2024.
 - Continued to build on its value-based care and clinical excellence leadership, including:
 - Breaking ground on IHH Singapore's first transitional care facility, TCF@East. The 200-bed facility complements IHH Singapore's 'out-of-hospital' strategy, extending the continuum of care available to patients.
 - Fortis Memorial Research Institute in India becoming South Asia's first to offer the groundbreaking Gamma Knife Esprit treatment for brain tumours.

H1 2024: Sustained core operational growth; strong financial position

- Revenue and EBITDA reported double-digit growth on sustained improvement in patient volumes and revenue intensity across all markets.
- Excluding exceptional items, PATMI (ex EI) was 30% higher.
- The lower headline PATMI was primarily due to the high base last year, which recorded one-off gains of RM862.0 million from the sale of International Medical University ("IMU").
- Balance sheet remained strong: net cash generated from operating activities at RM1.9 billion; overall cash balance at RM1.5 billion.

GROUP OUTLOOK

The ACE framework will continue to guide IHH's growth across five strategic priorities:



- The Group is confident of its growth trajectory and will anchor on its ACE framework to deliver against its five strategic priorities, notably aiming to add close to 4,000 new beds in the next five years.
- Overall, the Group expects continued revenue growth fuelled by healthcare megatrends and will focus on driving profitability and sustaining healthy ROE while maintaining prudent capital management and mitigating inflationary and interest rates pressures.

+++

ABOUT IHH HEALTHCARE BERHAD (“IHH”)

A world-leading integrated healthcare provider, IHH believes that making a difference starts with our aspiration to Care. For Good.

Our team of more than 70,000 people commit to deliver greater good to our patients, people, the public and planet, as we live our purpose each day to touch lives and transform care.

Through our portfolio of trusted brands – Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway – we offer our patients comprehensive and personalised care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging and rehabilitation.

With our scale and reach in 10 countries, we continue to raise the bar in healthcare in our key markets of Malaysia, Singapore, Türkiye, India, Greater China (including Hong Kong) and beyond.

In partnership with our stakeholders, we will co-create a sustainable future for all as we work towards our vision to become the world's most trusted healthcare services network.

More information can be found at www.ihhealthcare.com.

+++

For more information or to speak to an IHH spokesperson, please contact:

Penelope Koh
Investor Relations, IHH Healthcare
t. +65 9820 8973
e. penelope.koh@ihhhealthcare.com

Melissa Sim
WATATAWA Consulting
t. +65 9380 2938
e. msim@we-watatawa.com